Q2 2026 saw strong revenue and earnings growth, with both Evernorth and Cigna Healthcare outperforming expectations. Full-year adjusted EPS guidance was raised to at least $30.45, driven by specialty growth, biosimilar adoption, and disciplined execution.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.